✦ LIBER ✦

The Angiotensin Receptor Neprilysin Inhibitor LCZ696 in Heart Failure with Preserved Ejection Fraction: A Phase II Randomised-Controlled Trial

✍ Scribed by Scott D. Solomon; Michael Zile; Burkert Pieske; Adriaan A. Voors; Amil Shah; Elisabeth Kraigher-Krainer; Victor Shi; Toni Bransford; Madoka Takeuchi; Jianjian Gong; Martin Lefkowitz; Milton Packer; John J.V. McMurray

Book ID: 119214980
Publisher: Elsevier Science
Year: 2012
Tongue: English
Weight: 69 KB
Volume: 18
Category: Article
ISSN: 1532-8414
DOI: 10.1016/j.cardfail.2012.10.006

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

The angiotensin receptor neprilysin inhi

The angiotensin receptor neprilysin inhibitor LCZ696 in heart failure with preserved ejection fraction: a phase 2 double-blind randomised controlled trial

✍ Scott D Solomon; Michael Zile; Burkert Pieske; Adriaan Voors; Amil Shah; Elisabe 📂 Article 📅 2012 🏛 The Lancet 🌐 English ⚖ 353 KB

THE EFFICACY OF THE ANGIOTENSIN RECEPTOR

THE EFFICACY OF THE ANGIOTENSIN RECEPTOR NEPRILYSIN INHIBITOR, LCZ696, IN PATIENTS WITH HEART FAILURE WITH PRESERVED EJECTION FRACTION IS INDEPENDENT OF BLOOD PRESSURE LOWERING

✍ Jhund, Pardeep; Claggett, Brian; Packer, Milton; Zile, Michael; Voors, Adriaan; 📂 Article 📅 2014 🏛 Elsevier Science 🌐 English ⚖ 190 KB

Independence of the blood pressure lower

Independence of the blood pressure lowering effect and efficacy of the angiotensin receptor neprilysin inhibitor, LCZ696, in patients with heart failure with preserved ejection fraction: an analysis of the PARAMOUNT trial

✍ Jhund, Pardeep S.; Claggett, Brian; Packer, Milton; Zile, Michael R; Voors, Adri 📂 Article 📅 2014 🏛 Oxford University Press 🌐 English ⚖ 603 KB

Blood-pressure reduction with LCZ696, a

Blood-pressure reduction with LCZ696, a novel dual-acting inhibitor of the angiotensin II receptor and neprilysin: a randomised, double-blind, placebo-controlled, active comparator study

✍ Luis Miguel Ruilope; Andrej Dukat; Michael Böhm; Yves Lacourcière; Jianjian Gong 📂 Article 📅 2010 🏛 The Lancet 🌐 English ⚖ 377 KB

Myocardial viability as a determinant of

Myocardial viability as a determinant of the ejection fraction response to carvedilol in patients with heart failure (CHRISTMAS trial): randomised controlled trial

✍ JGF Cleland; DJ Pennell; SG Ray; AJ Coats; PW Macfarlane; GD Murray; J Dalle Mul 📂 Article 📅 2003 🏛 The Lancet 🌐 English ⚖ 107 KB

Rationale and design of the Treatment of

Rationale and design of the Treatment of Preserved Cardiac Function Heart Failure with an Aldosterone Antagonist Trial: A randomized, controlled study of spironolactone in patients with symptomatic heart failure and preserved ejection fraction

✍ Akshay S. Desai; Eldrin F. Lewis; Rebecca Li; Scott D. Solomon; Susan F. Assmann 📂 Article 📅 2011 🏛 Elsevier Science 🌐 English ⚖ 390 KB